论文部分内容阅读
继2012年羚羊感冒胶囊、斯达舒等药品卷入毒胶囊漩涡后,近日,修正药业又一明星产品肺宁颗粒因原料部分霉变引发药品安全质疑——这个宣称以“良心药、放心药、管用的药”为理念的医药集团,却屡次上演让消费者凉心的事件。11月15日,国家食品药品监督管理总局公布飞行检查结果,由于修正药业(柳河厂区)原料库存放的用于生产肺宁颗粒的药材返魂草部分发生霉变变质,且企业存在故意编造虚假检验报告等行为,已要求吉林省局依法收回其药品GMP(药品生产质量管理规范)证书。飞行检查即事先不通知被检查企业而对其实
Following the 2012 antelope cold capsules, Stoshu and other drugs involved in swirling drug capsules, recently, the amendment to another star product lung Ning pharmaceutical particles due to moldy part of the raw material led to drug safety questioned - the claim to “conscience medicine, Assured drug, drug in hand ”as the concept of the pharmaceutical group, but repeatedly staged consumer cool events. November 15, the State Food and Drug Administration announced the flight inspection results, due to amending the pharmaceutical (Liuhe plant) stock of raw materials used in the production of lung-ning particles resurfacing part of mildew metamorphism, and the presence of enterprises deliberately fabricated False inspection reports and other acts, has requested Jilin Province Bureau according to the law to recover its drug GMP (Drug Production Quality Management Code) certificate. Flight inspection that is not in advance to inform the inspected business and in fact